Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2017 by Vanderbilt-Ingram Cancer Center
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Pierre P. Massion, MD, Vanderbilt-Ingram Cancer Center
ClinicalTrials.gov Identifier:
NCT00897117
First received: May 9, 2009
Last updated: February 20, 2017
Last verified: February 2017

May 9, 2009
February 20, 2017
May 2001
July 2017   (Final data collection date for primary outcome measure)
Protein and RNA expression fingerprints from collected samples [ Time Frame: after collection of designated samples ]
  • Development of statistical and computational methods to model relationship of data and clinical outcomes
  • Protein and RNA expression fingerprints from collected samples
  • Correlation of protein and RNA expression fingerprints with recurrence (local and/or distant) and survival
Complete list of historical versions of study NCT00897117 on ClinicalTrials.gov Archive Site
  • Development of statistical and computational methods to model relationship of data and clinical outcomes [ Time Frame: after laboratory gene analysis work is completed ]
  • Correlation of protein and RNA expression fingerprints with recurrence (local and/or distant) and survival [ Time Frame: after collection of designated samples ]
Not Provided
Not Provided
Not Provided
 
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
Molecular Fingerprinting of Lung Cancer

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that may occur in RNA and identify biomarkers related to cancer.

PURPOSE: This research study is collecting and analyzing lung tissue samples from patients undergoing surgery for non-small cell lung cancer.

OBJECTIVES:

  • Develop statistical and computational methods for modeling the relationships between multiple variable protein and RNA expression data and clinical endpoints using both supervised and unsupervised classification and pattern recognition approaches.
  • Determine protein and RNA expression fingerprints on completely resected non-small cell lung cancer without prior chemotherapy.
  • Correlate protein and RNA expression fingerprints with T-stage and nodal involvement at the time of surgery, and collect outcome data to allow correlation with recurrence (local and/or distant) and survival.

OUTLINE: This is a multicenter study.

Any excess tissues removed from surgery and would otherwise be discarded (tissues not used for diagnosis and/or treatment decision making) are obtained for this study. Tissue are analyzed for molecular features that predict biologic behavior. Quantitation of RNA, gene expression profiles, and protein expression patterns are assessed by matrix-assisted laser desorption/ionization time of flight mass spectroscopy and microarray analysis.

Medical records are reviewed to obtain information about results of tests associated with cancer diagnosis. Further progress in cancer treatment and tumor behavior after surgery are followed via record review.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:
Both prospective and retrospectives samples of blood and tissue.
Probability Sample
People who have clinical stage I and II non-small cell lung cancer
Lung Cancer
  • Genetic: gene expression analysis
    Blood and lung tissue collection
  • Genetic: microarray analysis
    Blood and lung tissue collection
  • Genetic: protein expression analysis
    Blood and lung tissue collection
  • Other: biologic sample preservation procedure
    Blood and lung tissue collection
  • Other: laboratory biomarker analysis
    Blood and lung tissue collection
  • Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry
    Blood and lung tissue collection
Resectable non-small cell lung cancer
Patients with clinical stage I or II invasive lung cancer that can be completely removed by surgery and who have not undergone chemotherapy or radiotherapy before surgery
Interventions:
  • Genetic: gene expression analysis
  • Genetic: microarray analysis
  • Genetic: protein expression analysis
  • Other: biologic sample preservation procedure
  • Other: laboratory biomarker analysis
  • Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
1200
July 2017
July 2017   (Final data collection date for primary outcome measure)

Inclusion criteria

  • Diagnosis of non-small cell lung cancer

    • Clinical stage I and II disease
    • Resectable disease and complete surgical resection planned
  • Treated on companion studies at Vanderbilt University, the Veterans Administration hospital, St. Thomas, and Vanderbilt-Ingram Cancer Center Affiliate Network
  • Tumor specimen samples must be available at resection

Exclusion criteria

  • Chemotherapy before surgery
  • Radiotherapy before surgery
Sexes Eligible for Study: All
18 Years to 120 Years   (Adult, Senior)
No
Contact: VICC Clinical Trials Information Program 800-811-8480
United States
 
 
NCT00897117
VICC THO 0136
P50CA090949 ( US NIH Grant/Contract Award Number )
VU-VICC-THO-0136 ( Other Identifier: VICC )
P30CA068485 ( US NIH Grant/Contract Award Number )
No
Not Provided
Not Provided
Not Provided
Pierre P. Massion, MD, Vanderbilt-Ingram Cancer Center
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)
Principal Investigator: Pierre P. Massion, MD Vanderbilt-Ingram Cancer Center
Vanderbilt-Ingram Cancer Center
February 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP